During the past decade, Tennessee Oncology, PLLC conducted 215 clinical trials. In the 10-year time frame, 215 clinical trials started and 152 clinical trials were completed, i.e. on average, 70.7% percent of trials that started reached the finish line to date. In the past 5 years, 86 clinical trials started and 77 clinical trials were completed. i.e. 89.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tennessee Oncology, PLLC" #1 sponsor was "SCRI Development Innovations, LLC" with 105 trials, followed by "Pfizer" with 42 trials sponsored, "Eli Lilly and Company" with 35 trials sponsored, "Hoffmann-La Roche" with 27 trials sponsored and "Bristol-Myers Squibb" with 27 trials sponsored. Other sponsors include 126 different institutions and companies that sponsored additional 73 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tennessee Oncology, PLLC" #1 collaborator was "Genentech, Inc." with 27 trials as a collaborator, "Novartis" with 22 trials as a collaborator, "Bristol-Myers Squibb" with 11 trials as a collaborator, "GlaxoSmithKline" with 11 trials as a collaborator and "Bayer" with 9 trials as a collaborator. Other collaborators include 116 different institutions and companies that were collaborators in the rest 60 trials.

According to Clinical.Site data, the most researched conditions in "Tennessee Oncology, PLLC" are "Breast Cancer" (33 trials), "Multiple Myeloma" (17 trials), "Non-Small Cell Lung Cancer" (16 trials), "Metastatic Breast Cancer" (15 trials) and "Ovarian Cancer" (14 trials). Many other conditions were trialed in "Tennessee Oncology, PLLC" in a lesser frequency.

Most popular intervention types in "Tennessee Oncology, PLLC" are "Drug" (344 trials), "Biological" (38 trials), "Other" (11 trials), "Procedure" (6 trials) and "Radiation" (4 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (35 trials), "Placebo" (34 trials), "Paclitaxel" (27 trials), "Gemcitabine" (26 trials) and "Bevacizumab" (23 trials). Other intervention names were less common.

The vast majority of trials in "Tennessee Oncology, PLLC" are 315 trials for "All" genders, 34 trials for "Female" genders and 14 trials for "Male" genders.

Currently, there are NaN active trials in "Tennessee Oncology, PLLC". undefined are not yet recruiting, 57 are recruiting, 56 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 191 completed trials in Tennessee Oncology, PLLC, 2 suspended trials, and 48 terminated clinical trials to date.

Out of the total trials that were conducted in Tennessee Oncology, PLLC, 113 "Phase 1" clinical trials were conducted, 193 "Phase 2" clinical trials and 85 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 3 trials that are defined as “Not Applicable".